-+ 0.00%
-+ 0.00%
-+ 0.00%

Revenue Downgrade: Here's What Analysts Forecast For Pharma Mar, S.A. (BME:PHM)

Simply Wall St·11/20/2026 04:02:11
Listen to the news

Market forces rained on the parade of Pharma Mar, S.A. (BME:PHM) shareholders today, when the analysts downgraded their forecasts for next year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

After the downgrade, the seven analysts covering Pharma Mar are now predicting revenues of €267m in 2027. If met, this would reflect a notable 13% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of €302m in 2027. It looks like forecasts have become a fair bit less optimistic on Pharma Mar, given the measurable cut to revenue estimates.

See our latest analysis for Pharma Mar

earnings-and-revenue-growth
BME:PHM Earnings and Revenue Growth November 20th 2026

We'd point out that there was no major changes to their price target of €97.06, suggesting the latest estimates were not enough to shift their view on the value of the business.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. For example, we noticed that Pharma Mar's rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 10.0% growth to the end of 2027 on an annualised basis. That is well above its historical decline of 0.3% a year over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 14% annually for the foreseeable future. Although Pharma Mar's revenues are expected to improve, it seems that the analysts are still bearish on the business, forecasting it to grow slower than the broader industry.

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for Pharma Mar next year. They also expect company revenue to perform worse than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Pharma Mar after today.

Need some more information? We have estimates for Pharma Mar from its seven analysts out until 2028, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.